Methicillin resistant Staphylococcus aureus (MRSA) is a major health problem that has created a pressing need for new antibiotics. Compounds that inhibit the S. aureus SrtA sortase may function as potent antiinfective agents as this enzyme attaches virulence factors to the cell wall. Using high-throughput screening, we have identified several compounds that inhibit the enzymatic activity of the SrtA. A structureactivity relationship (SAR) analysis led to the identification of several pyridazinone and pyrazolethione analogs that inhibit SrtA with IC 50 values in the sub-micromolar range. Many of these molecules also inhibit the sortase enzyme from Bacillus anthracis suggesting that they may be generalized sortase inhibitors.
Introduction
The rise of community-and hospital-acquired methicillin resistant Staphylococcus aureus (MRSA) is a major health problem that has created a pressing need for new antibiotics. 1 More than 90,000 Americans acquire potentially deadly MRSA infections each year, which annually are estimated to kill more people than AIDS in the United States. 2 Proteins displayed on the surface of S. aureus play key roles in the infection process as they promote bacterial adhesion to host cells and tissue, acquire essential nutrients, and circumvent the immune response. 3 Most surface proteins in S. aureus are attached to the cell wall by the sortase A (SrtA) enzyme. [4] [5] [6] [7] [8] SrtA is located on the extracellular surface and catalyzes a transpeptidation reaction that joins an LPXTG sorting signal within the surface protein precursor to the cell wall precursor molecule lipid-II [undecaprenyl-pyrophosphate-MurNAc(-L-Ala-D-iGln-L-Lys (NH 2 -Gly 5 )-D-Ala-D-Ala)-b1-4-GlcNAc)]. [7] [8] [9] [10] The lipid-II linked protein product is then incorporated into the cell wall by the transglycosylation and transpeptidation reactions of cell wall synthesis. [11] [12] [13] Small molecules that inhibit the SrtA transpeptidation reaction may be powerful anti-infective agents as srtA À strains of S. aureus fail to display many virulence factors and exhibit reduced virulence. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] SrtA inhibitors may also be useful in treating infections caused by other Gram-positive pathogens, since many also use related enzymes to attach virulence factors to the cell wall and to assemble pili that promote bacterial adhesion. 25, 26 Sortases can be classified into five distinct families based on their primary sequence. 27 Enzymes most closely related to the S. aureus SrtA protein appear to be the best candidates for inhibitor development as their elimination in other bacterial pathogens attenuates virulence (e.g., Listeria monocytogenes, Streptococcus pyogenes, and Streptococcus pneumoniae (reviewed in Refs. 28, 29) ). Finally, SrtA is not required for the growth of S. aureus in cell cultures. Therefore, antiinfective agents that work by inhibiting SrtA could have a distinct advantage over conventional antibiotics as they may be less likely to induce selective pressure that leads to drug resistance. 7, 30 A number of different strategies have been employed to search for sortase inhibitors (reviewed in Refs. 28, 29, 31) . These include screening natural products [32] [33] [34] [35] [36] [37] [38] and small compound libraries, 39 as well as synthesizing rationally designed peptidomimetics and small molecules. [40] [41] [42] [43] [44] Recently, mechanism-based aryl (b-amino)ethyl ketone (AAEK) inhibitors have been reported. 39 AAEK molecules are specifically activated by sortase via a b-elimination reaction that generates an olefin intermediate that covalently modifies the active site cysteine thiol group. 39 However, these ported compounds also need to be optimized further to be therapeutically useful as they either have limited potency, undesirable physicochemical features (e.g., high molecular weights) or inactivate the enzyme slowly. 28, 29, 39 To identify potent inhibitors of SrtA we performed highthroughput screening (HTS) of a $30,000 compound library, which led to the identification of three promising small molecule inhibitors that can potentially be developed into anti-infective agents. A structure-activity relationship (SAR) analysis revealed several pyridazinone and pyrazolethione analogs that inhibit SrtA with IC 50 values in the sub-micromolar. These compounds are more potent than any previously described natural or synthetic inhibitor, and thus are excellent molecules for further development.
Results

High-throughput screening identifies several SrtA inhibitors
In order to screen for small molecule inhibitors of SrtA we modified a fluorescence resonance energy transfer (FRET) assay that monitors the SrtA-catalyzed hydrolysis of an internally quenched fluorescent substrate analog (o-aminobenzoyl (Abz)-LPETG-diaminopropionic acid-dinitrophenyl-NH 2 (Dap(Dnp)). The assay was miniaturized to enable its use in high-throughput screening (HTS). A typical progress curve is shown in Figure 1A . The calculated Z 0 score (a statistical measure of the assay's robustness) is 0.75, which indicates that the assay can be effectively used for screening. 45 The DiverSet library (ChemBridge Corp.) was screened for inhibitors of SrtA (see Section 4). Two criteria were used to calculate the inhibition percentage (% inhibition) of each compound in the library: (1) the initial velocity (m i ) of product formation calculated from reaction progress curves, and (2) an end-point determination of product formation obtained by measuring the total product fluorescence five hours after initiating the reaction. Compounds in the library were first ranked by their end-point readings.
This revealed a Gaussian distribution (Fig. 1B) , such that molecules that exhibit >55% enzyme inhibition can be considered as hits with a 99.7% confidence limit (their % inhibition value is at least three standard deviation units above the mean). 46 A total of 288 compounds met this criterion. The number of potential inhibitors was then further reduced by selecting only those molecules for which >80% inhibition was observed in the end-point analysis, as well as statistically significant inhibition when their m i values were considered (the m i value was less than or equal to 0 based on a 10 min progress curve). This reduced the total number of compounds to 44 (Fig. 1C ). Their inhibitory activity was then confirmed by manually repeating the FRET assay and they were ranked based on their % inhibition as determined by the end-point analysis. From this set, 10 compounds were selected for further study because they had the highest inhibitory activity and because they had physicochemical properties similar to known drugs. [47] [48] [49] [50] [51] [52] For these inhibitors, the concentration that is required to reduce the activity of SrtA by 50% (IC 50 ) was determined using well established methods. 34, 46, 53 The most potent SrtA inhibitors from this group are shown in Figure 2 (compounds 1-3) and were chosen for further study.
Analysis of the reversibility of inhibition of SrtA
For the three lead molecules, the reversibility of enzyme inhibition was determined by measuring the enzymatic activity of each enzyme-inhibitor complex immediately after it was rapidly diluted. 46 In this study SrtA was first incubated with saturating concentrations of each compound (inhibitor concentrations 10-fold higher than the IC 50 value). The SrtA-inhibitor complexes were then rapidly diluted and the enzyme activity immediately measured (data not shown). Inhibition by compound 1 is rapidly reversible as 84% of the enzyme activity is recovered after dilution. Compounds 2 and 3 also reversibly inhibit the enzyme, but more slowly; 50% and 58% activity is regained immediately after dilution, respectively. Mass spectrometry was also employed to confirm that the molecules form a reversible complex with the enzyme (described in Section 4). In this study, the mass spectrum of each saturated SrtA-inhibitor complex was recorded 1, 48, or 96 h after forming the complex. Mass spectra of these enzymeinhibitor complexes showed no difference from the negative control (SrtA alone), suggesting that the inhibitors do not stably modify the enzyme (data not shown). Detailed studies on inhibitory reversibility of the lead compounds and their derivatives are also being conducted in our laboratory and will be reported elsewhere.
Structure-activity relationship (SAR) analysis
An SAR analysis of the three lead compounds was performed to identify related molecules with increased potency. Initially, we purchased closely related analogs of the lead compounds from the ChemBridge Corp. and determined their IC 50 values against S. aureus SrtA. The analogs were identified through search of the company's database and share 75-95% similarity (based on the chemical functionality and scaffolding as determined by the company's similarity search engine) with one of the three lead compounds. A total of 7, 9, and 21 analogs of lead compounds 1, 2, and 3 were purchased and tested, respectively. This work enabled regions of the chemical scaffold required for inhibition to be coarsely defined. Analogs of the rhodanine 1 and pyridazinone 2 were then synthesized to make more subtle changes to discover molecules with even higher potency or better physicochemical properties. Eight analogs of 1 (compounds 1-8 to 1-13) and a total of 41 analogs of 2 were produced and tested (compounds 2-10 to 2-50). Tables 1-3 show the structures of all of the compounds that were tested and their IC 50 numbers. To gain insights into their selectivity, for several of the compounds we also measured their IC 50 values against the Bacillus anthracis sortase enzyme ( Ba SrtA).
A discussion of this data is presented below.
Synthesis and SAR of the rhodanine compounds (series 1)
Two scaffolds of the rhodanine compounds were examined by SAR (Table 1) . Compounds with scaffold A were purchased from ChemBridge Corp. (1 to 1-8), while compounds with scaffold B were synthesized in our laboratory (1-8 to 1-13). The synthesis of these compounds followed literature precedence, namely reaction of the N-alkyl isothiocyanate with methyl thioglycolate gave the 3-alkyl-4-oxothiazolidine-2-thiones. Condensation of these with the 5-arylfurfuraldehydes gave the compounds 1-8 to 1-13 in good yields. 54, 55 In scaffold A, replacing the 2,4-dimethyl groups on the R 2 position reduces the potency three-fivefold (compound 1
. On the other hand, relocating the 2-OH group on the R 3 position reduces the potency by 10-fold (compound 1 vs 1-4). These data suggest that these functional groups play a critical role in enzyme binding, presumably through hydrophobic interaction via the 2,4-dimethyl groups on the R 2 position, and hydrogen bonding via the 2-OH group at the R 3 position. The SAR results for compounds with scaffold B are in general agreement with this interpretation. Although these molecules retain the central rhodanine nucleus, they differ in the R 1 group and replace the R 3 group 
The compounds have been segregated into four subclasses. of compound 1 showed improved activity against SrtA and were not pursued further.
Synthesis and SAR of the pyridazinone compounds (series 2)
Initial SAR studies of lead compound 2 made use of derivatives purchased from ChemBridge (compounds 2-1 to 2-9) ( Table 2 ). This work revealed one of the most potent inhibitors of SrtA, compound 2-1 K lM). This discovery led us to investigate variants of these compounds by synthesizing several analogs (2-10 to 2-50). These compounds were prepared by an adaptation of the literature route, 56 namely heating a mixture of an arylhydrazine, mucochloric acid, and dilute HCl afforded the 2-aryl-4,5-dichloropyridazin-3-ones 2-42 to 2-48 in good yields (85-95%). The less reactive 4-nitrophenyl-hydrazine required more forcing conditions, namely a toluene solution of the initial formed hydrazone cyclization toluene was heated at reflux for 10 h using a Dean-Stark to afford the analog 2-43 in 76% yield for the two steps. The regioselectivity of the addition of oxygen nucleophiles to 2-42 to 2-48 was dependent on the conditions: use of 1,4-dioxane as the solvent, with sodium ethoxide or methoxide, afforded cleanly the 4-alkoxy products 2-22 to 2-34 (83-95% yield) while the use of sodium hydroxide in ethanol afforded cleanly the 5-ethoxy analogs 2-35 to 2-41 (75-94% yield). The assignment of the regiochemistry of the products was based on the observation of a strong NOE enhancement of the methylene of the ethyl signal in the 5-ethoxy compounds with the C5 vinyl hydrogen, an NOE which was absent from the 4-alkoxy compounds. The displacement of the remaining chloride atom in either the 4-or 5-alkoxy compounds was uneventful although we found that the reaction worked best in DMF as solvent. In this way the analogs 2-10 to 2-16 and 2-18 to 2-21 were formed. The symmetrical disulfide dimer, 2-17, could be formed by direct air oxidation of the thiol 2-10. The other disulfides were prepared by the reaction of the thiol 2-10 with methyl methanethiosulfonate (MMTS) or Aldrichthiol (2-pyridyldisulfide) to give 2-49 and 2-50 in yields of 88% and 65%, respectively. Finally the symmetrical disulfide 2-17 could also be prepared in 85% yield by reaction of the thiol 2-10 with the pyridyl disulfide 2-50. Substituents on the pyridazinone ring (R 1 and R 2 ) were suspected to contribute greatly to the inhibitory activity, as replacing the -SH with -OH at the R 1 position dramatically reduces potency (2 vs 2-7). Minor alteration of R 2 (from -OMe to -OEt) and removal of 3-Cl on the phenyl ring (R 4 ) also increase the potency more than 20-fold (compare 2 with 2-1). These observations suggest that the functional groups located on the pyridazinone ring may be as critical as those located on the phenyl ring. Therefore, we synthesized analogs with different substituents on the pyridazinone ring to optimize their potency further. Based on the substituent, these compounds are segregated into 4 subclasses: ethoxy-thiol (2-10 to 2-21); methoxy-chloro (2-22 to 2-27); ethoxy-chloro (2-28 to 2-41); and dichloro (2-42 to 2-48) pyridazinone compounds. Additionally, we also varied the R 3 and R 4 positions of each subclass in order to probe the importance of the phenyl ring. With the exception of compound 2-35, members of the ethoxy-thiol subclass are the most potent molecules. Within this series, switching the relative positioning of the R 1 and R 2 groups does not dramatically affect activity (compare 2-10 with 2-18, or 2-13 with 2-19, or 2-14 with 2-20). In contrast, varying the phenyl ring causes substantial changes in potency, with the lowest IC 50 obtained when all substituents are eliminated or when only small substituents are present. Interestingly, replacing entire phenyl ring with a cyclohexyl group did not profoundly alter activity (2-10 vs 2-16). This suggests that this portion of the ethoxy-thiol molecules may form non-specific hydrophobic interactions with the enzyme, which can be disrupted with groups larger than a phenyl or cyclohexyl ring are present. Because the ethoxy-thiol compounds all contain a thiol group that could potentially interact with the active site cysteine thiol of SrtA (residue Cys184) we created a series of molecules that are disulfide variants (compounds 2-17 in Table 2 , and 2-49, 2-50 in Fig. 3 ). Compound 2-17 is the symmetrical disulfide dimer of 2-10 and exhibits an approximately twofold increase in its potency. Interestingly, asymmetrical disulfide derivatives of 2-10 that contain methyl (2-49) or pyridyl (2-50) groups are even more potent and exhibit K app i values of $0.4 and 0.03 lM, respectively. In this series the pyridyl thiol is the best potential leaving group as it can be transformed into a stabilized pyridine-2-thione. As this derivative is the most potent inhibitor, this data suggest that these molecules may inhibit the enzyme through a thiol-disulfide exchange reaction involving Cys184. However, the mechanism of inhibition by these molecules remains unclear as compound 2 reversibly inhibits SrtA and does not modify the enzyme based on mass spectrometry data (described above). Although the 
SAR of the pyrazolethione compounds (series 3)
A series of pyrazolethione analogs of the lead compound 3 were obtained from ChemBridge through a similarity search. Inhibitory activities against SrtA were evaluated and are shown in Table 3 with the reduction in potency by a factor of 3-10 compared to the lead, suggesting inhibition may prefer the pyrazolethione nucleus and the phenyl ring on the nitrogen. strains. These compounds exhibit MIC values lower than ampicillin and cefotaxime and it has been proposed that they non-competitively inhibit penicillin-binding proteins. 59 The finding that compounds 2 and 3 do not affect bacterial growth is fortuitous, as nearly all of the potent SrtA inhibitors we identified in the SAR analysis are analogs of these molecules. In order to more rapidly ascertain SrtA inhibitory effects on microbial growth, we grew S. aureus cultures in the presence of 500 lM of each inhibitor and compared the rate of growth with control cultures grown in 2.5% DMSO (the solvent used to solubilize the inhibitors). This method enables an estimate of MIC to be obtained as molecules that do not affect bacterial growth can be assumed to have MIC values >1 mM. Consistent with the MIC data, compound 1 is toxic, while compounds 2 and 3 only modestly perturb growth (Fig. 4 ). An analysis of the growth data suggests that series 3 molecules are very promising anti-infective agents as four of its molecules inhibit SrtA with an IC 50 or K app i <5 lM, but otherwise do not substantially affect bacterial growth (compounds 3-1, 3-9, 3-12, and 3-17). Interestingly, the most potent SrtA inhibitor (compound 3-12) shows no detrimental effect to bacterial viability, highlighting its potential for further development as an anti-infective agent. Compounds in the 2-series show a variation of effects on S. aureus growth. The most promising candidates for further development are 2-9 and 2-20 as they inhibit SrtA with low micromolar IC 50 values and do not significantly inhibit S. aureus growth in cell culture.
The ability of several of the compounds to inhibit the sortase A protein from B. anthracis ( Ba SrtA) was tested to gain insights in their selectivity. This enzyme shares 27% amino acid sequence identity with S. aureus SrtA and also attaches proteins to the cell wall that contain an LPXTG sorting signal. 60 In addition, Ba srtA-knockout strains show defects in their ability to escape macrophages, suggesting that Ba SrtA may be useful in treating anthrax. 14 SrtA. Interestingly, compounds 2-9 and 2-20, which significantly impair S. aureus SrtA activity and are not bactericidal (Fig. 4) respectively. Combined these data suggest that the mechanism of 68 enzyme inhibition by compounds 2-9, 2-20, 3-9, and 3-12 is conserved across species, and that they are unlikely to significantly alter microbial processes other than surface protein display.
Biostructural analysis
To gain insight into the mode of binding of the SrtA inhibitors, we modeled how they interacted with the S. aureus SrtA enzyme using an Induced-Fit Docking (IFD) protocol (Schrödinger Inc.). [61] [62] [63] Compounds were docked into the recently determined solution structure of SrtA bound to a LPAT peptide. 64 After removal of the peptide coordinates the remaining protein structure was prepared for docking using the Protein Preparation Wizard, and LigPrep was used to prepare the ligand compounds. 63 The inhibitors were then docked into the SrtA receptor using a standard IFD workflow. Models of the SrtA-inhibitor complexes with the lowest negative IFD value were chosen to represent the final docking solution. When docked into the active site of SrtA, compound 1 inserts its hydrophobic moiety into the lipophilic pocket generated by the side chains of Ile199 in strand b8 and residues Val166 to Val168 in the adjacent b6/b7 loop (Fig. 5A ). This may explain why altering the 2,4-Me 2 groups at the R 2 position reduces potency three-fivefold.
On the rhodanine nucleus, the carbonyl oxygen is positioned toward the highly conserved side chain of Arg197, and its sulfide group is positioned toward His120. On the benzylidene ring, its 2-OH group is in close proximity to Trp194 and Tyr187 side chains, and its 5-NO 2 group is oriented toward His120, suggesting a potential hydrogen bonding network. This could explain the observed dramatic reductions in inhibitory activity when functional groups on the benzylidene ring are relocated (Table 1 , alterations to R 3 ).
For pyridazinone compounds (series 2), most of them bind to the active site in a similar orientation such that the phenyl ring is buried in the aforementioned lipophilic pocket. This is evident by comparing the docking solutions of compounds 2 (Fig. 5B) , 2-1 (Fig. 5C) and 2-35 (Fig. 5D ). These models provide a plausible explanation for why compound 2-1 has a K app i value $40-fold lower than compound 2, since the chloro group on the ring of compound 2 would seem to create a steric hindrance within this lipophilic pocket. Analogous to the docking solution observed for compound 1 (Fig. 5A) , the carbonyl oxygen atom on the pyridazinone ring in the docked complexes of 2, 2-1 and 2-35 are all positioned towards the conserved Arg197 side chain. In addition, the thiol group on both compounds 2 and 2-1 points towards His120, which may explain the significant reduction in activity when this group is replaced with a chloro group (compare ethoxy-thiol with ethoxy-chloro subclasses in Table 2 ). Interestingly, the docking solution of compound 2-35 suggests that it positions its ethoxy moiety toward another lipophilic region created by the side chains of Pro94 and Ala92 located in helix H1. This structural difference may explain the distinct SAR profiles observed within the ethoxy-chloro and ethoxy-thiol subclasses. The ethoxy-thiol subclass is more tolerant to alteration at this site, compatible with the docked solution that projects this group towards an open groove on the protein surface. In contrast, in the ethoxy-chloro series its juxtaposition against the helix H1 may make it less tolerant to alteration, which is compatible with our finding that only compound 2-35 within the ethoxy-chloro series has a low IC 50 value (vide supra).
The docking calculations suggest that the elongated structure of the series 3 compounds may be advantageous as it may enable contacts to two hydrophobic pockets on the enzyme. One phenyl ring (R 2 ) is in contact with the b6/b7 loop Val166-Val168 residues, while the other (R 3 ) is closer to Trp194 and Pro94 side chains (Fig. 5E ). Changing substituents on this R 3 position from 4-NO 2 to 2,4,6-Br 3 (compound 3-12) improved the potency $15-fold, indicating a preference for a more lipophilic moiety at this position.
However, replacing the substituent with 2,4-Me 2 or 3,4-Me 2 reduced potency, suggesting shape complementarity may be critical for binding. The docking solutions also suggest why the pyrazole nucleus may be specific to the sortase active site as its methyl and thione groups contact two highly conserved residues, Ala92 and Arg197, respectively (Fig. 5F ). This feature, along with their hydrophobic network, may be the reason why most of the compounds within this series exhibit high potency against SrtA enzymes, but little or no bactericidal activity.
Discussion
In this study we have identified several promising small molecules that reversibly inhibit the S. aureus SrtA sortase with K app i values in the high nanomolar range, rhodanine, pyrazolethione, and pyridazinone compounds. SAR analysis has led to some of the most promising anti-infective agents thus far reported as compounds 2-9 and 3-12 inhibit the enzyme with K but in some cases were bactericidal. Intriguingly, the most potent inhibitors for S. aureus SrtA also inhibit Ba SrtA, suggesting further that they are specific sortase inhibitors. Additional studies with more distantly related enzymes will be needed to define the degree of specificity. The library screening also revealed several rhodanine related compounds that are potent SrtA inhibitors. However, analogs of the lead molecule did not show improved potency. The lead rhodanine compound was also shown to be bactericidal, suggesting it has polytrophic effects. This is consistent with recent studies showing rhodanine compounds inhibit class C b-lactamases in Gram-negative bacteria 58 and penicillin-binding proteins in nonresistant S. aureus and MRSA strains. 59 Overall, the biostructural analysis of the inhibitors is in reasonable agreement with the SAR results, and provides insights into the mode of action of each inhibitor from the docking poses. This agreement may in part be due to the use of the recently reported NMR structure of SrtA bound to a (2R,3S) 3-amino-4-mercapto-2-butanol analog of the sorting signal. 64 The structure of the active site in this protein differs markedly from previously reported structures of the apo-form of the enzyme (PDB:1t2p) 65 and may be more biological relevant. This assertion is substantiated by trial docking experiments using the apo-form of the enzyme that failed to yield results consistent with the SAR data. The structure of the enzyme in its substrate bound form may therefore be useful for virtual screening experiments. In summary, we have discovered potent S. aureus and B. anthracis SrtA sortase inhibitors that could be useful anti-infective agents. Future studies will define their inhibitory mechanism in detail and use structure-based approaches to discover compounds with even greater potency.
Experimental
Chemistry
Materials were obtained from commercial suppliers and were used without purification. All the moisture sensitive reactions were conducted under argon atmosphere using oven-dried glassware and standard syringe/septa techniques. Most of reactions were monitored with a silica gel TLC plate under UV light followed by visualization with a p-anisaldehyde or ninhydrin staining solution. Some reactions were monitored by a crude 1 H NMR spectrum. 1 H NMR spectra were measured at 400 MHz in CDCl 3 unless stated otherwise and data were reported as follows in ppm (d) from the internal standard (TMS, 0.0 ppm): chemical shift (multiplicity, integration, coupling constant in Hz). 2D-NMR experiments (NOESY, COSY, and TOCSY) at 500 MHz were performed to confirm the regioselectivity of the substitution reactions. Melting Points of solid compounds were observed on a Thomas Hoover capillary melting point apparatus. Infrared (IR) spectra were recorded on a Nicolet AVATAR 370 spectrometer using liquid films (neat) on NaCl plates. The purity of the new compounds was assessed by several methods: high-field proton and carbon NMR (lack of significant impurities), R f values on TLC (lack of obvious impurities), melting point, and mass spectrometry.
4.1.1. General procedure for the synthesis of 2-substituted-4,5-dichloropyridazin-3-ones, for example, 2-phenyl-4,5-dichloropyridazin-3-one (2-42) To a solution of phenyl-hydrazine (2.9 mL, 30 mmol) in diluted HCl (4 M, 60 mL) was added mucochloric acid (5 g, 30 mmol) at 25°C. The solution was refluxed for 3 h. The suspension was filtered and washed with water. The solids were dried under high vacuum to give 7 g of the yellowish white solid, 2-42, 94%. 
To a solution of 4-nitrophenyl-hydrazine (4.6 mL, 30 mmol) in diluted HCl (4 M, 60 mL) was added mucochloric acid (5 g, 30 mmol) at 25°C. The solution was refluxed for 3 h. The suspension was filtered and washed with water to give the crude 2-43P. The yellow solids were subjected to the following cyclization reaction without further purification. The suspension of the crude 2-43P and p-toluenesulfonic acid (500 mg) in 200 mL of toluene was refluxed for 10 h. The solution was concentrated and the solids were washed with water to give 6.5 g of a yellowish solid, 2-43, 76% (two steps). 
4.1.2.
General procedure for the synthesis of 2-substituted 4-alkoxy-5-chloropyridazin-3-ones, for example, 5-chloro-4-ethoxy-2-phenylpyridazin-3-one (2-28) To a solution of 2-42 (200 mg, 0.809 mmol) in 6 mL of 1,4-dioxane was added 1 mL of freshly generated NaOEt (0.8 M) in EtOH (for methoxy substitution, NaOMe solution in MeOH was used) at 0°C. The suspension was stirred for 2 h as the solution was slowly warmed to 25°C. The suspension was concentrated and the mixture was subjected to flash column chromatography on silica gel to give 189 mg of 2-28, 92%. Mp 78°C. To a solution of 2-42 (200 mg, 0.809 mmol) in 6 mL of EtOH was added 0.8 mL of NaOH (1 M) at 0°C. The suspension was stirred for 2 h as it was allowed to warm to 25°C. The suspension was concentrated and the mixture was subjected to flash column chromatography on silica gel to give 195 mg of 2-35, 95%. Mp 110°C. To a solution of 2-28 (63 mg, 0.25 mmol) in 2 mL of DMF was added 70 mg of NaSH at 25°C. After TLC showed complete consumption of starting material, the solution was concentrated under high vacuum and diluted with 10 mL of water. The aqueous layer was washed with ethyl acetate and then pH of the aqueous layer was adjusted to 5-6 by addition of 1 M HCl (aq). Ethyl acetate (20 mL, two 10 mL portions) was added to the aqueous layer to extract the desired compounds. The organic layers were combined and dried over magnesium sulfate and concentrated to give 45 mg of 2-10 as a white solid, 73%. Mp 101°C. 1 at 25°C. The solution was stirred for 30 min and concentrated. The residual mixture was subjected to flash column chromatography on silica gel to give 6.1 mg of 2-49, 88%. To a solution of 2-10 (6 mg, 0.024 mmol) in 2 mL of MeOH was added aldrithiol (7.9 mg, 0.036 mmol) at 25°C. The solution was stirred for 2 h and concentrated. The residual mixture was subjected to flash column chromatography on silica gel to give 5.6 mg of 2-50, 65%. To a solution of 2-50 (10 mg, 0.028 mmol) in 2 mL of MeOH was added 15 mg of 2-10 at 25°C. The solution was stirred for 3 h then concentrated and subjected to flash column chromatography on silica gel to give 11.9 mg of 2-17, 85%. 
High-throughput screening
A total of 30,000 chemical compounds (DiverSet Chemically Diverse Library and Combichem Library, ChemBridge Corp.) were screened for S. aureus SrtA DN59 (residues 60-206) inhibition using an automated robotic system at the UCLA Molecular Screening Shared Resource facility. A fluorescence resonance energy transfer (FRET) assay was used in high-throughput screening in multi-well plates (384 wells per plate). 64 The assay monitors the SrtA DN59 -cat- 
Secondary assays
For the top ten lead compounds, the concentration that is required for a 50% reduction in enzymatic activity (IC 50 ) was determined using well established methods. 34 
Inhibitory binding reversibility study
The reversibility of inhibition was determined by measuring the recovery of enzymatic activity after a sudden large dilution of the enzyme-inhibitor complex. 46 11.25 lL of purified SrtA at a concentration of 150 lM was mixed with 1.25 lL of each inhibitor such that the final inhibitor concentration was 10-fold greater than its IC 50 . After incubation at 25°C for 1 h, 737.5 lL of FRET buffer was added. Thirty microliters of the diluted enzyme-inhibitor mixture were then plated and 20 lL of the fluorescent substrate (37.5 lM stock concentration) was added to initiate the cleavage reaction. The reaction progress curve was monitored as described above. Recovery of enzymatic activity after rapid dilution (100-fold) was calculated by comparing these progress curves with measurements of the reaction performed in the absence of inhibitor.
Mass spectrometry
Thirty microliters of purified SrtA (1.5 lM final assay concentration, dissolved in 5 mM CaCl 2 , 20 mM HEPES, pH 7.5 buffer)
were incubated with 1 lL of inhibitor such that the final inhibitor concentration was 1-and 10-fold higher than its IC 50 value. After incubating for 1, 48, or 96 h at 25°C, the enzyme-inhibitor mixture was mixed with an equal amount of a-cyano-4-hydroxycinnamic acid, and analyzed by MALDI-TOF using a Voyager-DE STR Biospectrometry Workstation (Applied Biosystems). An equal amount (1 lL) of DMSO was used instead of the inhibitor solution as a negative control. Cbz-LPAT* (where Cbz is a carbobenzyloxy protecting group and T* is a threonine derivative that replaces the carbonyl group with -CH 2 -SH) was used as a positive control, as it readily forms a disulfide bridge with the Cys184 thiol group of the enzyme. 41, 42 4.6. Determination of S. aureus MIC The minimal inhibitory concentration (MIC) was determined using the microtiter broth dilution method. 57 An overnight saturated culture of S. aureus strain Newman (provided by Dr. Lloyd Miller, Division of Dermatology, David Geffen School of Medicine, UCLA) was diluted to an OD 600 of 0.01. After additional incubation at 37°C and dilution to an OD 600 of 0.005, 180 lL of the culture was plated into a 96-well plate. Twenty microliters of inhibitor solution at varied concentrations (final concentrations of 0.1-100 lM) were then added to the culture. Cell growth was monitored by measuring the OD 600 during an overnight growth at 37°C using a temperature-controlled plate reader. The cell growth percentage was calculated relative to cultures gown in the absence of inhibitor as well as in the presence of 10 lg/mL erythromycin. MIC measurements were performed in triplicate.
Molecular docking
Molecular docking of each inhibitor was performed using Schrödinger Suite 2008 63 with an Induced-Fit Docking (IFD) workflow. 61, 62 Calculations were run on a PC equipped with 3.8 GHz Intel Hyperthreading CPU, 2.0 GB SDRAM memory, and a LINUX operating system. The IFD protocol can be summarized as follows. First, the Glide docking module scales the van der Waals radii for both ligand and receptor binding site atoms by 50%. Second, the Prime module restores, predicts, and energy minimizes 20 structures of the given ligand-receptor complex generated by the first step. Finally, the ligand conformations are redocked into the induced-fit receptor structures generated by the second step. Complex structures possessing energies that are within 30 kcal/mol were then ranked and the IFD scores determined. The poses presented in the paper are those conformations with the best score. The receptor protein structure was prepared by the Protein Preparation Wizard in Maestro user interface (Schrödinger, LLC). 63 The bond orders were assigned, and the charges and hydrogen bonds were optimized by using the default protocol. All inhibitor ligands were prepared by the LigPrep 63 module in a comparable manner.
